Jefferies London 2026: A top biotech CEO (Roivant's Matt Gline) and top investor (Affinity Asset Advisors' Patrick Nosker) talk running biotech companies and investing in them
Jefferies London 2026: A top biotech CEO (Roivant's Matt Gline) and top investor (Affinity Asset Advisors' Patrick Nosker) talk running biotech companies and investing in them
They discuss Roivant's structure and programs (a top holding of Affinity's) and how different investors view companies different ways. Plus, the ups and downs of biotech, and why it is rare for smaller biotech companies to grow into larger entities over the long run.
AI 伴隨問答
針對這篇報導有疑問?可直接點選快捷問題或向 AI 追問背景脈絡與技術細節:
Podcast 專家音訊節目
收錄於 888news Podcast 智庫專區,包含精華摘要與上市公司即時行情
They discuss Roivant's structure and programs (a top holding of Affinity's) and how different investors view companies different ways. Plus, the ups and downs of biotech, and why it is rare for smaller biotech companies to grow into larger entities over the long run.